Intelsat’s Global, Multi-Layered High-Throughput FlexMaritime Service Expands Into Indian Territorial Waters
22.11.2021 13:00:00 EET | Business Wire | Press release
Intelsat, operator of the world's largest integrated satellite and terrestrial network, announces the expansion of its global FlexMaritime service, now enabling connectivity for vessels traveling in Indian territorial waters and immediately enhancing the service coverage for all of Intelsat’s 8,000 existing FlexMaritime vessels. The landmark development also provides access for Indian-registered vessels to Intelsat’s award-winning global high-throughput maritime network. Intelsat's expansion is made possible by a new in-country gateway that is operationally ready to provide service via Intelsat’s HTS satellites under India-based partner Cloudcast's In-Flight and Maritime Connectivity (IFMC) license.
FlexMaritime provides high-speed, resilient connectivity service with 99.95% proven network uptime. The expansion of FlexMaritime into India will open new business opportunities and accelerate digital transformation for thousands of Indian-flagged vessels and ships trading in Indian territorial waters. According to the Ministry of Shipping, around 95% of India's trading by volume and 70% by value is done through maritime transport.
"The completion of this regulatory milestone means customers of our FlexMaritime solutions partners will immediately benefit from the well-known power, performance and resilience of the FlexMaritime service in Indian waters," said Intelsat Senior Vice President of Mobility, Mark Rasmussen. "The network expansion also demonstrates Intelsat's commitment to mobility services providing yet another new dimension of global trade with access for Indian companies."
Intelsat has experienced continued growth in its FlexMaritime service. More than 8,000 vessels benefit from unrivaled network density and a global, multi-layered high-throughput satellite (HTS) fabric that enables partners to create unique service packages at enterprise-grade performance levels. With terminal sizes of 37cm, 45cm, 60cm and 1 meter, FlexMaritime meets the connectivity needs of every type of vessel with scale and global reach, even in high-traffic port locations.
The gateway will be located in Noida, India, serving as a critical link between Intelsat's terrestrial ground network and space assets and extending Intelsat's existing global network to a vital trading port.
Services are slated for availability at the beginning of 2022 through Intelsat's many solutions partners.
About Intelsat
As the foundational architects of satellite technology, Intelsat operates the world's most trusted satellite telecom network. We apply our unparalleled expertise and global scale to connect people, businesses and communities, no matter how difficult the challenge. Intelsat is building the future of global communications with the world's first hybrid, multi-orbit, software-defined 5G network designed for simple, seamless, and secure coverage precisely when and where our customers most need it. Follow the leader in global connectivity and "Imagine Here," with us, at Intelsat.com.
About Cloudcast
Cloudcast is a 100% subsidiary of Planetcast Media Services Limited and is focused on growing the business in satellite communications and promoting excellence in Value Added Services, Business Practices, Technology and Operations. Cloudcast has commercial licenses for VSAT, ISP, and the new IFMC Gateway Services in India. Planetcast, the parent company, has over the years been instrumental in providing cutting-edge technology to enhance broadcast services. The Planetcast Group's ability to conceptualize, architect, and implement new and expanded capabilities allows clients to take their business to the next level. It is a key market player in providing technology-led managed services to the broadcasting industry in India.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122005896/en/
Contact information
Media:
Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom